ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS

書誌詳細
主要な著者:	Adams, R, Maughan, T, Smith, C, Seymour, M, Wilson, R, Meade, A, Fisher, D, Madi, A, Kenny, S, Wasan, H, Rogers, P, Hodgkinson, E, Jasani, B, Cheadle, J, Kaplan, R
フォーマット:	Journal article
出版事項:	2009

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
著者:: Maughan, T, 等
出版事項: (2009)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
著者:: Adams, R, 等
出版事項: (2009)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
著者:: Maughan, T, 等
出版事項: (2010)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
著者:: Maughan, T, 等
出版事項: (2010)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
著者:: Madi, A, 等
出版事項: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
著者:: Madi, A, 等
出版事項: (2012)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
著者:: Maughan, T, 等
出版事項: (2011)

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL
著者:: Madi, A, 等
出版事項: (2010)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
著者:: Wasan, H, 等
出版事項: (2011)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
著者:: Adams, R, 等
出版事項: (2009)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
著者:: Adams, R, 等
出版事項: (2010)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
著者:: Adams, R, 等
出版事項: (2011)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
著者:: Adams, R, 等
出版事項: (2008)

A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS
著者:: Vale, C, 等
出版事項: (2009)

Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
著者:: Vale, C, 等
出版事項: (2009)

HIGH THROUGHPUT SOMATIC PROFILING OF THE RAS-RAF-MAP AND PI3K-PTEN-AKT PATHWAYS IN ADVANCED COLORECTAL CANCER AND CORRELATIONS WITH RESPONSE TO CETUXIMAB
著者:: Smith, C, 等
出版事項: (2010)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
著者:: Taieb, J, 等
出版事項: (2012)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
著者:: Wood, G, 等
出版事項: (2017)

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
著者:: Smith, C, 等
出版事項: (2013)

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab
著者:: Madi, A, 等
出版事項: (2017)

Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
著者:: Seymour, M, 等
出版事項: (2007)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
著者:: Elli Narvi, 等
出版事項: (2018-11-01)

FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS and NRAS
著者:: Adams, R, 等
出版事項: (2016)

Design and development of information portal for Asian Communication Resource Centre (ACRC).
著者:: Yohanes Ramli.
出版事項: (2008)

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy
著者:: West, H, 等
出版事項: (2018)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
著者:: Seymour, M, 等
出版事項: (2011)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
著者:: Bai L, 等
出版事項: (2019-12-01)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
著者:: Madi, A, 等
出版事項: (2018)

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
著者:: Susan D. Richman, 等
出版事項: (2011-01-01)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
著者:: Seymour, M, 等
出版事項: (2007)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
著者:: J. M. Short, 等
出版事項: (2023-09-01)

Oxaliplatin-Loaded Chitosan Nanoparticles Decorated with Cetuximab Single-Chain Variable Fragment for Human Colorectal Cancer Treatment
著者:: Khadijeh Falahzadeh, 等
出版事項: (2024-09-01)

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
著者:: Akari Hashimoto, 等
出版事項: (2014-05-01)

Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
著者:: Moe, M, 等
出版事項: (2008)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
著者:: Maughan, T, 等
出版事項: (2010)

Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer
著者:: Gray, V, 等
出版事項: (2019)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
著者:: John Pradeep Veluchamy, 等
出版事項: (2016-01-01)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
著者:: Wing-Lok Chan, 等
出版事項: (2014-01-01)

A NOVEL COLORECTAL CANCER SUSCEPTIBILITY SNP IN THE EIF3H PROMOTER INFLUENCES PATIENT SURVIVAL AND RESPONSE TO TREATMENT
著者:: Cheadle, J, 等
出版事項: (2010)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
著者:: Erik J. vanHelden, 等
出版事項: (2019-11-01)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS

類似資料

類似資料